



September 25, 2025

Dear Colleagues,

I am writing to inform you that I will be stepping back from my Managing Director role at Broadview Ventures at the end of this year. Broadview has been extraordinarily successful in achieving its mission, has a strong team in place, and is well positioned for the future.

In 2007, I was introduced to the Leducq Charitable Trust leadership by my then boss at Mass General Brigham, Dr. Eugene Braunwald. The Trust was looking to further its mission of improving the health of patients with cardiovascular disease and stroke. Shortly thereafter, I accepted the role of founding Managing Director of Broadview Ventures charged with building a mission-based, early-stage investment program targeting cardiovascular disease and stroke.

In 2009, Broadview made its very first seed investment in CardiAQ Valve Technologies which was subsequently acquired by Edwards Lifesciences and formed the basis for EVOQUE, the first FDA approved transcatheter tricuspid valve replacement, now helping patients worldwide. Since then, Broadview has established itself as a leader in early-stage cardiovascular and stroke investing, with a team of outstanding professionals dedicated to helping entrepreneurs accelerate bringing cutting edge science to patients.

Broadview now evaluates 700 proposals annually and has invested in and supported 56 companies worldwide. For every dollar Broadview invests, its companies leverage 27 more. Our active portfolio raised over \$1 billion of outside funding over the last two years. In 2019, we created Longview Ventures as a follow-on investment vehicle to extend its support to Broadview portfolio companies. We are fortunate to invest alongside the leading venture firms and interact daily with the world's thought leaders in cardiovascular medicine — all in support of Broadview's patient-focused mission. And just this month, Edwards Lifesciences acquired Vectorious, a Broadview-seeded, Israeli company promising to change the treatment paradigm for heart failure by enabling patient self-management of diuretics.

And while Broadview is thriving, continuing its work has never been more important given the ongoing challenges to funding for innovation. And so, I write to you with succession plans that look to the future to meet these challenges, build upon Broadview's successes, and maximize the impact it can have for patients.

Having had the honor of working for the Leducq Trust and leading Broadview for 18 years, I have achieved what I set out to do — and now is an ideal time for me to explore my next chapter. With a stellar team in place to serve Broadview's mission, I will relinquish day-to-day management responsibilities in 2026 but stay on to serve Broadview in a part-time capacity, focused on professional development of the team and advancement of the Broadview strategy and mission. With the balance of my time, I'll pursue new professional

and personal activities consistent with my passion for advising and mentoring high impact causes, leaders, and organizations. Broadview's future is not one without me — just a scaled-back version continuing to provide significant guidance and support to the investment team and portfolio.

To that end, I am very pleased to announce the internal promotions of Thomas Needham and Daniel Gottlieb to Managing Directors of Broadview. Tom joined Broadview in 2018 as a Director and Head of BioPharma, with 30 years of biotech industry and venture investing experience. Daniel joined Broadview in 2019 and is a Director in the MedTech practice, with 25 years of MedTech corporate venture and operating experience. Their combined talents — along with their strength of character and long history at Broadview — make them ideal choices to lead Broadview into the future.

Broadview has achieved more than I ever imagined possible. Its mission, investment model, professional team, and domain knowledge are established and flourishing. I sincerely thank the Leducq Trust for the opportunity to lead Broadview and for its unwavering support of its mission. And I am deeply grateful to all of you who have supported Broadview and from whom I have learned so much over these years.

Please join me in congratulating Tom and Daniel on their new leadership positions. I look forward to supporting them and continuing to work with you as Broadview forges new ground to meet its mission of improving human health in patients with cardiovascular disease and stroke.

About Broadview Ventures

Broadview Ventures is a mission-driven investment organization that makes targeted investments in early-stage companies to accelerate the development of innovative therapeutics, devices, and diagnostics for cardiovascular disease and stroke. Broadview is funded by The Leducq Charitable Trust.

To learn more about Broadview's portfolio and activities, please visit our [website](#).

Broadview Ventures | 265 Franklin Street | Boston, MA 02110 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!